This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fudin, J. Articles by Boutin, R. Search for Related Content PubMed PubMed Citation Articles by Fudin, J. Articles by Boutin, R. Social Bookmarking                         What's this?

Use of continuous ambulatory infusions of concentrated subcutaneous (SQ) hydromorphone versus intravenous (IV) morphine: Cost implications for palliative care

Dept. of Pharmacy, Stratton VA Medical Center, Albany, New York

Howard S. Smith, MD

Cancer Pain and Palliative Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

Charlotte S. Toledo-Binette, BS, RPh

Quantum Health Resources, Albuquerque, NM

Ellen Kenney, BS, PharmD, RPh

Andrew B.C. Yu, PhD

Food and Drug Administration, Washington, DC

Ronald Boutin, BS, PharmD, BCPS

St. Peter’s Hospital, Albany, New York

Health care practitioners are increasingly under pressure to curtail spending while trying to deliver excellent patient care. These issues are also affecting palliative care, particularly now that palliative care programs are expanding. A comparison of cost-effectiveness and feasibility of using continuous subcutaneous (SQ) ambulatory infusion of hydromorphone versus intravenous (IV) ambulatory morphine is illustrated in this study. With the high doses of morphine required in chronic cancer pain, the use of subcutaneous morphine is not feasible due to the volume of solution required to be delivered. Hydromorphone can be prepared in concentrated solutions enabling it to be delivered by the subcutaneous route. Morphine stability data are available. However, hydromorphone stability has only been verified for seven days; thus, stability data were needed post-seven days. Concentrations of 10 mg/ml, 20 mg/ml, 50 mg/ml, and 100 mg/ml, in 0.9 percent normal saline or dextrose 5 percent water, were analyzed via high-performance liquid chromatography (HPLC) at seven and 28 days. Cost comparisons of supplies and associated costs with subcutaneous versus intravenous solutions were obtained. Hydromorphone was found to be stable for 28 days in both dilutents. Cost analysis of a hydromorphone 28-day supply resulted in substantial savings over the equivalent costs of morphine infusions.

American Journal of Hospice and Palliative Medicine®, Vol. 17, No. 5, 347-353 (2000)
DOI: 10.1177/104990910001700513


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?